🚑 Glenmark Pharmaceuticals Expands U.S. Injectable Portfolio with New Potassium Phosphate Launch

Indian pharma major Glenmark Pharmaceuticals continues to strengthen its presence in the U.S. generics market with the upcoming launch of Potassium Phosphates Injection USP through its U.S. subsidiary. 📦 Product Launch Details The company announced the launch of multiple strengths of Potassium Phosphates Injection in the U.S. market, including: • 15 mmol P / 22 mEq K per 5 mL single-dose vial • 45 mmol P / 66 mEq K per 15 mL single-dose vial • 150 mmol P / 220 mEq K per 50 mL pharmacy bulk package The product is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi. 📊 Market Opportunity According to IQVIA data, the U.S. market for these formulations recorded approximately $50.7 million in annual sales for the 12-month period ending January 2026. 🔬 Strategic Significance This launch further strengthens Glenmark’s institutional injectable portfolio in North America, supporting hospitals and healthcare providers with quality and affordable alternatives. With growing focus on injectables and complex generics, Glenmark continues to expand its global pharmaceutical footprint. 💬 Investor Takeaway: Incremental product launches in regulated markets like the U.S. help diversify revenue streams and strengthen Glenmark’s generics pipeline. Glenmark Pharmaceuticals 👍 Like | 🔁 Share | ➕ Follow for more market insights ⚠️ Disclaimer: This post is for informational purposes only and should not be considered investment advice. Please consult a registered financial advisor before making investment decisions.